{"id":3631,"date":"2022-03-18T04:47:43","date_gmt":"2022-03-18T04:47:43","guid":{"rendered":"https:\/\/aceoncology.org\/?p=3631"},"modified":"2022-03-18T04:48:30","modified_gmt":"2022-03-18T04:48:30","slug":"fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/","title":{"rendered":"\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457"},"content":{"rendered":"\n<p>\u968f\u7740\u9776\u5411B\u7ec6\u80de\u53d7\u4f53\u4fe1\u53f7\u548c\u6297\u51cb\u4ea1\u86cb\u767dBCL2\u7684\u65b0\u578b\u53e3\u670d\u5236\u5242\u7684\u5f15\u5165\uff0c\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5(CLL)\u7684\u6cbb\u7597\u683c\u5c40\u53d1\u751f\u4e86\u663e\u8457\u53d8\u5316\u3002\u5176\u4e2d\u5305\u62ec\u5e03\u9c81\u987f\u6c0f\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5242\u4f0a\u5e03\u66ff\u5c3c\u548cBcl-2\u6291\u5236\u5242\u7ef4\u5948\u514b\u62c9\uff0c\u4e8c\u8005\u5747\u5df2\u83b7\u6279\u4f5c\u4e3a\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08 CLL\uff09\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08SLL\uff09\u5355\u836f\u6cbb\u7597\u6216\u4e0e\u6297CD20\u6297\u4f53\u5229\u59a5\u6614\u5355\u6297\u6216\u5965\u59a5\u73e0\u5355\u6297\u8054\u5408\u6cbb\u7597\u3002\u4f0a\u5e03\u66ff\u5c3c\u548c\u7ef4\u5948\u514b\u62c9\u5355\u836f\u6cbb\u7597\u901a\u5e38\u8010\u53d7\u6027\u826f\u597d\uff0c\u4e14\u6bd2\u6027\u7279\u5f81\u4e0d\u91cd\u53e0\u3002\u6b64\u5916\uff0c\u4e34\u5e8a\u524d\u7814\u7a76\u53d1\u73b0\u5176\u6f5c\u5728\u7684\u534f\u540c\u6d3b\u6027\uff0c\u8fd9\u4f7f\u5f97\u7814\u7a76\u8005\u5f00\u542f\u4e86CLL\/SLL\u8054\u5408\u6cbb\u7597\u7684\u63a2\u7d22\u3002<\/p>\n\n\n\n<p>\u8be5\u591a\u4e2d\u5fc3\u3001II\u671fCAPTIVATE\u7814\u7a76\u5728\u4e24\u4e2a\u72ec\u7acb\u7684\u961f\u5217\u4e2d\u63a2\u7d22\u4e86\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u4f5c\u4e3aCLL\/SLL\u7684\u4e00\u7ebf\u6cbb\u7597\uff0c\u5176\u4e2d\u4e00\u4e2a\u961f\u5217\u91c7\u53d6\u5fae\u5c0f\u6b8b\u7559\u75c5\u7076\uff08MRD\uff09\u6307\u5bfc\u4e0b\u7684\u968f\u673a\u6cbb\u7597\uff0c\u53e6\u4e00\u4e2a\u961f\u5217\u91c7\u53d6\u56fa\u5b9a\u7597\u7a0b\uff08FD\uff09\u3002\u4e24\u4e2a\u961f\u5217\u5747\u5165\u7ec470\u5c81\u53ca\u4ee5\u4e0b\u7684\u60a3\u8005\uff0c\u5148\u63a5\u53d73\u4e2a\u5468\u671f\u7684\u4f0a\u5e03\u66ff\u5c3c\u5bfc\u5165\u671f\uff08\u6bcf\u65e5420 mg\uff09\u6cbb\u7597\uff0c\u7136\u540e\u63a5\u53d712\u4e2a\u5468\u671f\u7684\u4f0a\u5e03\u66ff\u5c3c\uff08\u6bcf\u65e5420 mg\uff09\u4e0e\u7ef4\u5948\u514b\u62c9\uff08\u6807\u51c65\u5468\u5242\u91cf\u9012\u589e\u540e\u6bcf\u65e5400 mg\uff09\u8054\u5408\u6cbb\u7597\u3002MRD\u961f\u5217\u4e2d\u786e\u8ba4\u65e0\u6cd5\u68c0\u6d4b\u5230\u5fae\u5c0f\u6b8b\u7559\u75c5\u7076\uff08uMRD\uff09\u7684\u60a3\u8005\u968f\u673a\u63a5\u53d7\u4f0a\u5e03\u66ff\u5c3c\u6216\u5b89\u6170\u5242\u6cbb\u7597\uff1b\u672a\u8fbe\u5230\u786e\u8ba4\u7684uMRD\u60a3\u8005\u7ee7\u7eed\u63a5\u53d7\u4f0a\u5e03\u66ff\u5c3c\u6216\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u7684\u6cbb\u7597\u3002<a href=\"https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.21.00807\">\u8be5\u961f\u5217\u7684\u7ed3\u679c\u4e4b\u524d\u5df2\u6709\u62a5\u544a<\/a>\uff0c75%\u7684\u60a3\u8005\u5728\u5916\u5468\u8840\uff08PB\uff09\u4e2d\u8fbe\u5230uMRD\uff0c68%\u7684\u60a3\u8005\u5728\u9aa8\u9ad3\uff08BM\uff09\u4e2d\u8fbe\u5230uMRD\uff0c\u5728\u968f\u540e\u7684MRD\u6307\u5bfc\u4e0b\u7684\u968f\u673a\u6cbb\u7597\u4e2d\uff0c30\u4e2a\u6708\u65e0\u8fdb\u5c55\u751f\u5b58\u7387\uff08PFS\uff09\u59cb\u7ec8\u8d85\u8fc795%\u3002<\/p>\n\n\n\n<p><a href=\"https:\/\/ashpublications.org\/blood\/article\/doi\/10.1182\/blood.2021014488\/484114\/Fixed-duration-ibrutinib-plus-venetoclax-for-first\">\u56fa\u5b9a\u7597\u7a0b\uff08FD\uff09\u961f\u5217\u7684\u7ed3\u679c\u4e8e\u8fd1\u671f\u53d1\u8868<\/a>\u3002\u603b\u4f53\u800c\u8a00\uff0c159\u4f8b\u60a3\u8005\u5165\u7ec4\u8be5\u961f\u5217\uff0c\u5305\u62ec136\u4f8b\u65e0del\uff0817p\uff09\u7684\u60a3\u8005\u3002\u5927\u90e8\u5206\u60a3\u8005\u5177\u6709\u4e00\u4e2a\u6216\u591a\u4e2a\u98ce\u9669\u56e0\u7d20\uff0c\u5305\u62ecdel\uff0817p\uff09\u548c\/\u6216TP53\u7a81\u53d8\u3001del\uff0811q\uff09\u548cIGHV\u57fa\u56e0\u65e0\u7a81\u53d8\u3002\u4e3b\u8981\u7ec8\u70b9\u662f\u7814\u7a76\u8005\u8bc4\u4f30\u7684\u65e0del\uff0817p\uff09\u60a3\u8005\u7684\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u7387\uff0cCR\u7387\u4e3a56%\uff08p &lt; 0.0001\uff09\u3002\u5728\u6240\u6709\u6cbb\u7597\u4eba\u7fa4\u548c\u5927\u591a\u6570\u9ad8\u98ce\u9669\u4e9a\u7ec4\u4e2d\u89c2\u5bdf\u5230\u76f8\u4f3c\u7684CR\u7387\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c99%\u5145\u5206\u968f\u8bbf\u7684\u60a3\u8005\u7ef4\u6301CR\u8d85\u8fc712\u4e2a\u5468\u671f\u3002\u9664\u9ad8CR\u7387\u5916\uff0c\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u8fd8\u5728\u5916\u5468\u8840\uff08PB\uff09\u548c\u9aa8\u9ad3\uff08BM\uff09\u4e2d\u4ea7\u751f\u4e86\u8f83\u9ad8\u7684uMRD\u7387\uff0c\u8fd9\u4e0eMRD\u961f\u5217\u7684\u7ed3\u679c\u4e00\u81f4\u3002\u5728\u6240\u6709\u6cbb\u7597\u4eba\u7fa4\u4e2d\uff0cPB\u548cBM\u7684\u6700\u4f73uMRD\u7387\u5206\u522b\u4e3a77%\u548c60%\u3002\u5305\u62ec\u5177\u6709\u9ad8\u98ce\u9669\u56e0\u7d20\u7684\u60a3\u8005\u5728\u5185\uff0c\u5404\u60a3\u8005\u4e9a\u7ec4\u7684uMRD\u7387\u8f83\u9ad8\u3002\u4e2d\u4f4d\u968f\u8bbf27.9\u4e2a\u6708\uff0c24\u4e2a\u6708PFS\u7387\u548c\u603b\u751f\u5b58\u7387\u5206\u522b\u4e3a95%\u548c98%\u3002\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u65b9\u6848\u8010\u53d7\u6027\u826f\u597d\uff0c92%\u7684\u60a3\u8005\u5b8c\u6210\u4e86\u5b8c\u6574\u7684\u56fa\u5b9a\u7597\u7a0b\u65b9\u6848\u6cbb\u7597\u3002FD\u961f\u5217\u7684\u5b89\u5168\u6027\u7279\u5f81\u4e0eMRD\u961f\u5217\u62a5\u544a\u7684\u5b89\u5168\u6027\u7279\u5f81\u76f8\u4f3c\uff0c\u672a\u89c2\u5bdf\u5230\u65b0\u7684\u5b89\u5168\u6027\u4fe1\u53f7\u3002\u4ec5\u5c11\u6570\u60a3\u8005\u9700\u8981\u51cf\u5c11\u5242\u91cf\u6216\u505c\u7528\u4e00\u79cd\u6216\u4e24\u79cd\u6cbb\u7597\u836f\u7269\u3002\u91cd\u8981\u7684\u662f\uff0c\u4f0a\u5e03\u66ff\u5c3c\u5bfc\u51653\u4e2a\u5468\u671f\u7684\u51cf\u7624\u6548\u679c\u964d\u4f4e\u4e86\u9ad8\u80bf\u7624\u8d1f\u8377\u60a3\u8005\u6bd4\u4f8b\uff0c\u9ad8\u80bf\u7624\u8d1f\u8377\u60a3\u8005\u5f80\u5f80\u5177\u6709\u8f83\u9ad8\u7684\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81\uff08TLS\uff09\u98ce\u9669\u3002\u56e0\u6b64\uff0c\u7531\u4e8e\u76d1\u6d4b\u548c\u9884\u9632TLS\u800c\u4f4f\u9662\u7684\u60a3\u8005\u6bd4\u4f8b\u4ece\u57fa\u7ebf\u65f6\u768440%\u964d\u81f3\u4f0a\u5e03\u66ff\u5c3c\u5bfc\u5165\u671f\u540e18%\u3002<\/p>\n\n\n\n<p>\u57fa\u4e8e\u8fd9\u4e9b\u7ed3\u679c\uff0c\u4f5c\u8005\u5c06\u4f0a\u5e03\u66ff\u5c3c\u548c\u7ef4\u5948\u514b\u62c9\u7684\u6cbb\u7597\u7ec4\u5408\u63cf\u8ff0\u4e3a\u201c\u4e00\u79cd\u5168\u53e3\u670d\u3001\u6bcf\u65e5\u4e00\u6b21\u3001\u65e0\u5316\u7597\u3001\u56fa\u5b9a\u7597\u7a0b\u7684\u6cbb\u7597\u65b9\u6848\uff0c\u53ef\u4ea7\u751f\u6df1\u5ea6\u3001\u6301\u4e45\u7684\u7f13\u89e3\uff0c\u5e76\u53ef\u5728\u95e8\u8bca\u4e2d\u4e3a\u5927\u591a\u6570\u5e74\u8f7b\u9002\u5408\u7684CLL\/SLL\u60a3\u8005\u63d0\u4f9b\u201d\u3002\u4ed6\u4eec\u6307\u51fa\uff0c\u7531\u4e8eCLL\u60a3\u8005\u7684\u603b\u4f53\u4eba\u7fa4\u5e74\u9f84\u504f\u5927\uff0c\u5408\u5e76\u75c7\u66f4\u591a\uff0cCAPTIVATE\u7814\u7a76\u7684\u7ed3\u679c\u53ef\u80fd\u4e0d\u592a\u9002\u7528\u4e8e\u8fd9\u4e9b\u60a3\u8005\u3002\u5728FD\u65b9\u6848\u540e\u590d\u53d1\u7684\u60a3\u8005\u4e2d\uff0c\u4f5c\u8005\u89c2\u5bdf\u5230\u4f0a\u5e03\u66ff\u5c3c\u5355\u836f\u518d\u6cbb\u7597\u7684\u53cd\u5e94\u826f\u597d\uff0cBTK\u3001PLCg2\u6216BCL-2\u7f3a\u4e4f\u8010\u836f\u76f8\u5173\u7a81\u53d8\u3002<\/p>\n\n\n\n<p><strong>\u53c2\u8003\u6587\u732e<\/strong><br>Tam C et al. <em>Blood. <\/em>2022 Feb 23. [Online ahead of print].<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u968f\u7740\u9776\u5411B\u7ec6\u80de\u53d7\u4f53\u4fe1\u53f7\u548c\u6297\u51cb\u4ea1\u86cb\u767dBCL2\u7684\u65b0\u578b\u53e3\u670d\u5236\u5242\u7684\u5f15\u5165\uff0c\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5(CLL)\u7684\u6cbb\u7597\u683c\u5c40\u53d1\u751f\u4e86\u663e [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":3566,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[88,2],"tags":[],"class_list":["post-3631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-88","category-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457 - ACE Oncology<\/title>\n<meta name=\"description\" content=\"\u53e3\u670d\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u56fa\u5b9a\u7597\u7a0b\u4e00\u7ebf\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u88ab\u8bc1\u5b9e\u7597\u6548\u663e\u8457\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457 - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"\u53e3\u670d\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u56fa\u5b9a\u7597\u7a0b\u4e00\u7ebf\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u88ab\u8bc1\u5b9e\u7597\u6548\u663e\u8457\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-18T04:47:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-18T04:48:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/03\/Blog-Picture-81-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1918\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ACE Demo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ACE Demo\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/\"},\"author\":{\"name\":\"ACE Demo\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\"},\"headline\":\"\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457\",\"datePublished\":\"2022-03-18T04:47:43+00:00\",\"dateModified\":\"2022-03-18T04:48:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/\"},\"wordCount\":77,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/03\/Blog-Picture-81-scaled.jpg\",\"articleSection\":[\"\u6587\u7ae0\u7cbe\u534e\",\"\u6587\u7ae0\u7cbe\u8981\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/\",\"name\":\"\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457 - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/03\/Blog-Picture-81-scaled.jpg\",\"datePublished\":\"2022-03-18T04:47:43+00:00\",\"dateModified\":\"2022-03-18T04:48:30+00:00\",\"description\":\"\u53e3\u670d\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u56fa\u5b9a\u7597\u7a0b\u4e00\u7ebf\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u88ab\u8bc1\u5b9e\u7597\u6548\u663e\u8457\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/03\/Blog-Picture-81-scaled.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/03\/Blog-Picture-81-scaled.jpg\",\"width\":2560,\"height\":1918},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\",\"name\":\"ACE Demo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"caption\":\"ACE Demo\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457 - ACE Oncology","description":"\u53e3\u670d\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u56fa\u5b9a\u7597\u7a0b\u4e00\u7ebf\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u88ab\u8bc1\u5b9e\u7597\u6548\u663e\u8457","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/","og_locale":"zh_CN","og_type":"article","og_title":"\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457 - ACE Oncology","og_description":"\u53e3\u670d\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u56fa\u5b9a\u7597\u7a0b\u4e00\u7ebf\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u88ab\u8bc1\u5b9e\u7597\u6548\u663e\u8457","og_url":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/","og_site_name":"ACE Oncology","article_published_time":"2022-03-18T04:47:43+00:00","article_modified_time":"2022-03-18T04:48:30+00:00","og_image":[{"width":2560,"height":1918,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/03\/Blog-Picture-81-scaled.jpg","type":"image\/jpeg"}],"author":"ACE Demo","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"ACE Demo","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/"},"author":{"name":"ACE Demo","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0"},"headline":"\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457","datePublished":"2022-03-18T04:47:43+00:00","dateModified":"2022-03-18T04:48:30+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/"},"wordCount":77,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/03\/Blog-Picture-81-scaled.jpg","articleSection":["\u6587\u7ae0\u7cbe\u534e","\u6587\u7ae0\u7cbe\u8981"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/","url":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/","name":"\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457 - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/03\/Blog-Picture-81-scaled.jpg","datePublished":"2022-03-18T04:47:43+00:00","dateModified":"2022-03-18T04:48:30+00:00","description":"\u53e3\u670d\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u56fa\u5b9a\u7597\u7a0b\u4e00\u7ebf\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u88ab\u8bc1\u5b9e\u7597\u6548\u663e\u8457","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/03\/Blog-Picture-81-scaled.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/03\/Blog-Picture-81-scaled.jpg","width":2560,"height":1918},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/fixed-duration-treatment-ibrutinib-venetoclax-first-line-cll\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"\u56fa\u5b9a\u7597\u7a0b\u4f0a\u5e03\u66ff\u5c3c\u8054\u5408\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u7597\u6548\u663e\u8457"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0","name":"ACE Demo","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","caption":"ACE Demo"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/3631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=3631"}],"version-history":[{"count":2,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/3631\/revisions"}],"predecessor-version":[{"id":3634,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/3631\/revisions\/3634"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/3566"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=3631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=3631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=3631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}